To Investigate The Method Of Diagnosis Of Prostate Cancer (a Report Of210Cares)

Purpose：Prostate cancer is one of the common urological malignancy. In recentyears, studies show that the incidence of prostate cancer is rising. Throughretrospective clinical study designed to compare the advantages and disadvantages ofvarious prostate cancer screening method in order to improve its diagnosis.Method：Collected in our hospital between2009to2013by the pathology ofprostate cancer patients identified210cases analyzed with clinical data, application AJCC TNM staging system staging, comparing the diagnostic methods, such as digitalrectal examination, serum PSA testing, prostate biopsy, etc., statistical methods of eachvariable frequency expressed as a percentage, comparing rates, comparative analysis ofcount data using the chi-square test, P <0.05considered statistically significant.Result：1.210cases of prostate cancer patients, aged52-86years, mean age was72years.Where: less than60years of age group15(7.1%), between60to80years143cases(68.1%), more than80years in52cases (24.8%).2. There are197cases of clinical symptoms (93.8%),95cases of patients withsymptoms including hematuria (45.2%), lower urinary tract symptoms185cases(88.1%)(including dysuria, urinary urgency and urinary retention, dysuria, etc.), noclinical symptoms prostatic hyperplasia due to physical or pathological stumbled upon13cases (6.2%).例stages T1-28(3.8%), T3-4202cases (96.2%). Whole body bonescan showed metastasis89cases (67.4%),43cases without metastasis (32.6%).3. Serum tPSA values>4ng/ml190patients (90.5%);<4ng/ml20patients (9.5%);4-10ng/ml13patients (6.2%);>10ng/ml177patients (84.3%;, f/t>0.16for the30cases(14.3%),<0.16for the180cases (85.7%)210patients with clinical stage and thecorresponding serum PSA values were: T1-28例, PSA (14.7±2.0) ng/ml; T3103.patients, PSA (62.4±5.3) ng/ml; T499例, PSA (89.4±10.6); correlation andregression analysis showed: PSA was significantly associated with clinical stage (P<0.001).4.210cases of Bank of whole body bone scan132cases and found89cases ofbone metastasis (67.4%),43cases without metastasis (32.6%), whichever is thethreshold PSA value20ng/ml predict prostate cancer bone metastasis sensitivity,specificity and accuracy were respectively87.6%(78/89),67.4%(29/43) and81.1%(107/132).5.210cases of patients underwent DRE examination, prostate cancer ischaracterized by DRE palpable nodules or hard, this group of113cases of prostatecancer prompted DRE (53.4%). 6.210cases of BOC6needle biopsy in31cases, of which30cases of pathologicalresults were positive, the positive biopsy rate was96.8%.7. The group of210prostate cancer cases BOC CT examination138cases, ofwhich the results of CT diagnosis of prostate cancer in49cases, the diagnostic accuracyof35.5%, where the different clinical stages CT diagnostic accuracy rates were: T1-2i1/8cases (12.5%), T3-4-48/202cases (23.8%); OK MRI41例, MRI results of32cases of prostate cancer diagnosis, the diagnostic accuracy of78.0%; amongdifferent clinical stages MRI diagnostic accuracy rates were: T1-2期3/8cases(37.5%), T3-4maturity of38/202cases (14.4%).Conclusion：1.60-80years of age for the high incidence of prostate cancer in men beginning atage50should be an annual routine PSA testing and DRE examination. Serum PSA lessthan10ng/ml, should be combined with the patient’s age, closely followed up f/t ratioand further examination.2. PSA values have clinical significance in predicting prostate cancer bonemetastasis, when PSA greater than20ng/ml, bone metastasis great possibility. DREand PSA testing for prostate cancer in combination can increase the rate of positivediagnosis.3Transrectal prostate biopsy can confirm the diagnosis, PSA is normal butpositive DRE, should be as early as possible biopsy.4.CT and MRI-positive rate of prostate cancer diagnosis is not enough, but it isimportant in the staging diagnosis.5.May be part of the normal PSA for prostate cancer.